These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25583753)

  • 1. Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.
    Demeester S; Keymeulen B; Kaufman L; Van Dalem A; Balti EV; Van de Velde U; Goubert P; Verhaeghen K; Davidson HW; Wenzlau JM; Weets I; Pipeleers DG; Gorus FK
    Diabetes Care; 2015 Apr; 38(4):644-51. PubMed ID: 25583753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
    Keymeulen B; van Maurik A; Inman D; Oliveira J; McLaughlin R; Gittelman RM; Roep BO; Gillard P; Hilbrands R; Gorus F; Mathieu C; Van de Velde U; Wisniacki N; Napolitano A
    Diabetologia; 2021 Feb; 64(2):313-324. PubMed ID: 33145642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
    Aronson R; Gottlieb PA; Christiansen JS; Donner TW; Bosi E; Bode BW; Pozzilli P;
    Diabetes Care; 2014 Oct; 37(10):2746-54. PubMed ID: 25011949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials.
    De Grijse J; Asanghanwa M; Nouthe B; Albrecher N; Goubert P; Vermeulen I; Van Der Meeren S; Decochez K; Weets I; Keymeulen B; Lampasona V; Wenzlau J; Hutton JC; Pipeleers D; Gorus FK;
    Diabetologia; 2010 Mar; 53(3):517-24. PubMed ID: 20091020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
    Keymeulen B; Vandemeulebroucke E; Ziegler AG; Mathieu C; Kaufman L; Hale G; Gorus F; Goldman M; Walter M; Candon S; Schandene L; Crenier L; De Block C; Seigneurin JM; De Pauw P; Pierard D; Weets I; Rebello P; Bird P; Berrie E; Frewin M; Waldmann H; Bach JF; Pipeleers D; Chatenoud L
    N Engl J Med; 2005 Jun; 352(25):2598-608. PubMed ID: 15972866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of antibodies against IA-2β and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age.
    Vermeulen I; Weets I; Asanghanwa M; Ruige J; Van Gaal L; Mathieu C; Keymeulen B; Lampasona V; Wenzlau JM; Hutton JC; Pipeleers DG; Gorus FK;
    Diabetes Care; 2011 Aug; 34(8):1760-5. PubMed ID: 21715527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies against insulin measured by electrochemiluminescence predicts insulitis severity and disease onset in non-obese diabetic mice and can distinguish human type 1 diabetes status.
    Lo B; Swafford AD; Shafer-Weaver KA; Jerome LF; Rakhlin L; Mathern DR; Callahan CA; Jiang P; Davison LJ; Stevens HE; Lucas CL; White J; von Borstel R; Todd JA; Lenardo MJ
    J Transl Med; 2011 Nov; 9():203. PubMed ID: 22123298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-titer autoantibodies against glutamic acid decarboxylase plus autoantibodies against insulin and IA-2 predicts insulin requirement in adult diabetic patients.
    Kasuga A; Maruyama T; Nakamoto S; Ozawa Y; Suzuki Y; Saruta T
    J Autoimmun; 1999 Mar; 12(2):131-5. PubMed ID: 10047433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline plasma proinsulin response to glucose for predicting therapeutic response to otelixizumab in recent-onset type 1 diabetes.
    Desouter AK; Keymeulen B; Demeester S; Van de Velde U; De Pauw P; Van Dalem A; Lapauw B; De Block C; Gillard P; Pipeleers DG; Gorus FK
    Diabetes Res Clin Pract; 2023 Nov; 205():110974. PubMed ID: 37884063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple screening method for individuals at risk of developing type 1 diabetes: measurement of islet cell autoantibodies (GADA, IA-2A, and IAA) on dried capillary blood spots collected on filter paper.
    Siraj ES; Rogers DG; Gupta MK; Reddy SS
    Horm Metab Res; 2012 Oct; 44(11):855-60. PubMed ID: 22893260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?
    Fouts A; Pyle L; Yu L; Miao D; Michels A; Krischer J; Sosenko J; Gottlieb P; Steck AK;
    Diabetes Care; 2016 Oct; 39(10):1738-44. PubMed ID: 27456836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies to insulin, insulinoma-associated antigen-2, and zinc transporter 8 improve the prediction of early insulin requirement in adult-onset autoimmune diabetes.
    Kawasaki E; Nakamura K; Kuriya G; Satoh T; Kuwahara H; Kobayashi M; Abiru N; Yamasaki H; Eguchi K
    J Clin Endocrinol Metab; 2010 Feb; 95(2):707-13. PubMed ID: 20061424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study.
    Ambery P; Donner TW; Biswas N; Donaldson J; Parkin J; Dayan CM
    Diabet Med; 2014 Apr; 31(4):399-402. PubMed ID: 24236828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and
    Gorus FK; Balti EV; Messaaoui A; Demeester S; Van Dalem A; Costa O; Dorchy H; Mathieu C; Van Gaal L; Keymeulen B; Pipeleers DG; Weets I;
    Diabetes Care; 2017 Aug; 40(8):1065-1072. PubMed ID: 28701370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.
    Guglielmi C; Williams SR; Del Toro R; Pozzilli P
    Expert Opin Biol Ther; 2016 Jun; 16(6):841-6. PubMed ID: 27145230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short duration of breast-feeding as a risk-factor for beta-cell autoantibodies in 5-year-old children from the general population.
    Holmberg H; Wahlberg J; Vaarala O; Ludvigsson J;
    Br J Nutr; 2007 Jan; 97(1):111-6. PubMed ID: 17217566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility.
    Pöllänen PM; Lempainen J; Laine AP; Toppari J; Veijola R; Vähäsalo P; Ilonen J; Siljander H; Knip M
    Diabetologia; 2017 Jul; 60(7):1284-1293. PubMed ID: 28364254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes.
    Decochez K; Truyen I; van der Auwera B; Weets I; Vandemeulebroucke E; de Leeuw IH; Keymeulen B; Mathieu C; Rottiers R; Pipeleers DG; Gorus FK;
    Diabetologia; 2005 Apr; 48(4):687-94. PubMed ID: 15756536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes In Finland Study Group.
    Sabbah E; Savola K; Kulmala P; Veijola R; Vähäsalo P; Karjalainen J; Akerblom HK; Knip M
    J Clin Endocrinol Metab; 1999 May; 84(5):1534-9. PubMed ID: 10323375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An improved clinical model to predict stimulated C-peptide in children with recent-onset type 1 diabetes.
    Buchanan K; Mehdi AM; Hughes I; Cotterill A; Le Cao KA; Thomas R; Harris M
    Pediatr Diabetes; 2019 Mar; 20(2):166-171. PubMed ID: 30556344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.